Papillomaviruses and cervical cancer: pathogenesis and vaccine development.
A subset of human papillomaviruses (HPVs) has been implicated as the principal etiologic agents of cervical cancer. Cervical cancers consistently retain and express two of the viral genes, E6 and E7. Although infection with HPV seems to be necessary, other factors, such as cellular immune function, play an important role in determining whether cervical infection will regress, persist, or progress to cancer. The close relationship between viral infection and cancer makes HPV an attractive target for prophylactic and therapeutic vaccines. Candidate vaccines have been shown to have efficacy in animal models, and human clinical trials are planned or in progress.
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD, USA.
D R
DR
Lowy
J T
JT
Schiller
D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000276:immunology*; D053918:Papillomavirus Vaccines; D014412:Tumor Virus Infections / Q000150:complications* / Q000517:prevention & control / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control / Q000821:virology*; D014765:Viral Vaccines / Q000627:therapeutic use
D019496:Cancer Vaccines; D053918:Papillomavirus Vaccines; D014765:Viral Vaccines